For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid
lineage (red blood cells, platelets, and white blood cells other than B and T cells). Like other …

Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic …

Molecular measurable residual disease (MRD) assessment is not established in
approximately 60% of acute myeloid leukemia (AML) patients because of the lack of suitable …

Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy
historically have poor outcomes. Approximately 12–15% of older patients with AML harbor …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The
pathophysiology of this disease is just beginning to be understood at the cellular and …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Abstract Since 2001, the World Health Organization classification for hematopoietic and
lymphoid neoplasms has provided a framework for defining acute leukemia (AL) subtypes …

Acute myeloid leukemia (AML) is organized as a cellular hierarchy initiated and maintained
by a subset of self-renewing leukemia stem cells (LSC). We hypothesized that increased …

Purpose Half the patients with acute myeloid leukemia (AML) who achieve complete
remission (CR), ultimately relapse. Residual treatment-surviving leukemia is considered …